

# Constructing stabilized dynamic treatment regimens using electronic health record data

Yingqi Zhao

Fred Hutchinson Cancer Research Center

Oct 25, 2016

2nd Seattle Symposium on Health Care Data Analysis

# Outline

- 1 Motivation
- 2 Dynamic treatment regimes
- 3 Stabilized dynamic treatment regimes
- 4 Other challenges

# Diabetes

- Current diabetes guidelines: tight control of glycosylated hemoglobin (A1c) ( $< 7\%$ )
  - Healthy patients.
  - Based on trials of younger patients without severe diabetes complications or other comorbidities.
  - Relatively low risk of tight control; significant benefits in reducing incidence of vascular events
  - Tight control of BP ( $< 130/80$  mm Hg) and LDL cholesterol ( $< 100$  mg/dl) for patients with diabetes

# Diabetes

- Inappropriate for complex diabetes patients, i.e., older patients (age > 65 years) and/or those with comorbid conditions.
  - Evidence for these guidelines was mainly obtained from the results of randomized clinical trials (RCTs)
  - Complex patients usually meet the exclusion criteria of clinical trials
  - Increased risk of drug-related morbidity, e.g., hypoglycemia, hypotension

# Diabetes

- Guidelines recognize that less stringent treatment goals may be appropriate for complex diabetes patients, and recommend individualization in treatments based on clinical experiences.
- How can we strengthen the current guidelines for complex patients?
- Opportunities: large electronic health records systems

## A1c control observational study (PI: Smith, Maureen)

- Linked claims and EHR data for Medicare beneficiaries in the University of Wisconsin Medical Foundation (UWMF) system.
  - Met a validated algorithm for identifying patients with diabetes via claims (each claim contains information associated with the services or procedures performed, e.g., ICD-9-CM diagnosis codes);
  - Medically homed at the participating large, Midwestern, multi-specialty provider group
  - UWMF EHR systems: detailed clinical results including laboratory values and vital signs
- 8,304 diabetes patients active during 2003-2011, recorded each 90-day quarter in which they were alive at the start of the quarter

# Data

- A1c values recorded in the EHR.
- Outcome: adverse outcomes occurring during these quarters (e.g., emergency department use or hospitalizations, death), documented from claims information.
- Covariates: sociodemographics, and indicators for comorbidities; time varying patient complexity: the presence of chronic kidney disease (CKD) or congestive heart failure (CHF)

## Data




Figure 1: Risk of multiple events.

## Data

How to target tight A1c control for these patients?





Figure 2: A1c level over time.

# Dynamic Treatment Regime

- At any decision point
  - Input: available historical information on the patient to that point.
  - Output: next treatment.
- Dynamic treatment regimes (DTRs) are sequential decision rules for individual patients that can adapt over time to an evolving illness.
  - One decision rule for each time point.
  - Each rule: recommends the treatment at that point as a function of accrued historical information.
  - An algorithm for treating any patient.
  - Aim to optimize some cumulative clinical outcome.

## DTR Goals

Learn adaptive treatment strategies: tailor (sequences of) treatments based on patient characteristics.



Maximize the benefit of dynamic treatment regimes:

- Well chosen tailoring variables.
- Well devised decision rules.

## Dynamic Treatment Regimes (DTRs)

Observe data on  $n$  individuals,  $T$  stages for each individual,

$$X_1, A_1, R_1, X_2, A_2, \dots, X_T, A_T, R_T, X_{T+1}$$

- $X_1$ : Initial information.
- $X_t$ : Intermediate information between stages  $t - 1$  and  $t$ ,  $t \geq 2$ .
- $A_t$ : Observed treatment received at stage  $t$ , e.g., tight control A1c or not,  $A_t \in \{0, 1\}$ .
- $R_t$ : Observed outcome following stage  $t$ , e.g., ED visits, hospitalizations or deaths following stage  $t$ .
- $H_t$ : History available at stage  $t$ ,  
 $H_t = \{X_1, A_1, R_1, \dots, A_{t-1}, R_{t-1}, X_t\}$ .


A DTR is a sequence of decision rules:

$$d = (d_1(H_1), \dots, d_T(H_T)), d_t(H_t) \in \{0, 1\}.$$


# Multi-stage Data

 $H_1$


# Multi-stage Data




# Multi-stage Data




# Multi-stage Data




# Multi-stage Data




# Multi-stage Data




# Multi-stage Data



# Multi-stage Data



# Multi-stage Data



## Dynamic Treatment Regimes

An example of desired regime:

Target tight A1c control on patients with A1c level  $> 7.5\%$  who does not have CKD/CHF

Mathematically, the formal rule is

$$d_t(H_t) = I(A1c_t > 7.5\% \ \& \ CKD_t = 0 \ \& \ CHF_t = 0).$$

The treatment decision rule at each decision point is the same function of the time-varying covariate(s), also called shared decision (Chakraborty et al (2016))

# Value Function and Optimal DTR for Multiple Stages


## Goal

Maximize (minimize) the **expected sum of outcomes** if the DTR is followed by all patients in the population.

- The **value function**:  $\mathcal{V}(d) = E^d(R_1 + \dots + R_T)$ .
- Optimal DTR:  $d^* = \operatorname{argmax}_d \mathcal{V}(d)$ .
- Two main challenges in developing optimal DTRs:
  - Taking **individual** information into account in decision making.
  - Incorporating **long-term** benefits and risks of treatment due to delayed effects.


# Dynamic Programming

- Estimate  $d^*$  if one knows the complete probability distribution of data generation.




# Dynamic Programming

- Estimate  $d^*$  if one knows the complete probability distribution of data generation.




# Dynamic Programming

- Estimate  $d^*$  if one knows the complete probability distribution of data generation.




# Dynamic Programming

- Estimate  $d^*$  if one knows the complete probability distribution of data generation.



# Dynamic Programming

- Estimate  $d^*$  if one knows the complete probability distribution of data generation.



## Construct a DTR via Q-learning

- An extension of regression to sequential treatments.
- Q learning with regression: estimate the Q-functions from data using regression and then find the optimal DTR.
- Decision not shared; rely on the assumption that models are correct.

# Stabilized Dynamic Treatment Regimes

- Learn the optimal DTRs at all stages simultaneously.
- Identify an estimator of  $\mathcal{V}(d)$ , and directly maximize  $\hat{\mathcal{V}}(d)$  over  $d \in \mathcal{D}$ , where  $\mathcal{D}$  is a prespecified class of DTRs of interest, e.g., linear DTRs
- An inverse probability of treatment estimator (IPWE) of  $\mathcal{V}(d)$

$$\hat{\mathcal{V}}^{IPWE}(d) = \mathbb{P}_n \left( \frac{(\sum_j R_j) I\{A_j = d_j(H_j), j = 1, \dots, T\}}{\prod_{j=1}^T P(A_j = d_j(H_j) | H_j)} \right).$$

# Stabilized Dynamic Treatment Regimes

- Let  $d_t(h_t) = I(h_t^T \beta > 0)$  and find  $\hat{\beta}$  that maximizes  $\hat{V}^{IPWE}(d)$ .
- Replace a concave surrogate for the indicator to alleviate the computation difficulties.
- $P(A_t|H_t)$  can be estimated using e.g., logistic regression
- Apply the LASSO penalty for sparsity.

## Simulation Studies: Generative Model

- Baseline covariates  $X_{1,1}, \dots, X_{1,50} \sim N(0, 1)$
- $X_{t,1} = X_{t-1,1} + N(0, 1), j \geq 2.$
- $\text{logit}(P(A_t = 1|H_t)) = 2X_t - 1$
- $Y \sim 10 + X_{1,1}X_{1,2} + X_{1,3} - \sum_{t=1}^4 |2X_{t,1} - 3|\{I(A_t > 0) - I(X_{t,1}^3 - 0.5 > 0)\}^2 + N(0, 1).$
- Optimal decisions:  $d_t^*(h_t) = \text{sign}(X_{t,1} - 0.79)$

## Simulation Studies

- Training data sample size 1000.
- Testing data sample size 10000.
- 500 replications.
- Evaluate using the values of the estimated DTRs.

## Simulation Studies


	$n = 1000$
SDTR	8.66
Q learning	5.47
Shared Q learning	7.81

# Medication regimes

- Large number of combinations of therapies are possible
- Use pharmacy claims to identify individual medications
- Group medications into therapeutic classes and identify the most frequent drug regimens


## Missing data

- A significant portion of our data set is missing.



## Missing data

- A significant portion of our data set is missing.



# Missing Data

- EHR data are collected in a non-prescheduled fashion only when the patient seeks care or the physician orders care, creating a situation with intermittent missing data.
- The visiting process could be potentially informative about the patients' risk categories; not missing at random.

## Multiple imputation

- The missing data are filled in  $m$  times to generate  $m$  complete data sets
- Estimate the optimal stabilized DTR using each complete data set.
- Results from the  $m$  complete data sets are combined.
- Fully Conditional Specification/Bayesian Mixed Effects Method to impute (Shortreed et al, 2014)
- Explore Bayesian multiple imputation approach and pattern mixture model methods.

Thanks!